Brian Smith, MD
Hematology · Bridgeton, MONPI 1598144917
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Beigene USA, Inc. at 55.4% of the total. 2024 is the largest year on record at $1,803, 9.9 times the $181 reported in 2019.
Across 73 payments — averaging $40.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$2K
- Daiichi Sankyo Inc.$271
- Johnson & Johnson$198
- Novartis$94
- Seagen Inc.$86
- Pharmacyclics LLC, An Abbvie Company$84
- plus $598 from 17 others
Across 7 payments — averaging $6119.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$43K
What the payments were for
- Consulting fees$1,65055%
- Food & beverage$1,24142%
- Education$903%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 1 | $1,650 |
| Daiichi Sankyo Inc. | 18 | $271 |
| Johnson & Johnson | 10 | $198 |
| Novartis | 5 | $94 |
| Seagen Inc. | 4 | $86 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $84 |
| Bristol Myers Squibb | 5 | $72 |
| Mirati Therapeutics, Inc. | 4 | $61 |
| Merck | 3 | $60 |
| Stemline Therapeutics Inc. | 3 | $58 |
| Jazz Pharmaceuticals Inc. | 1 | $56 |
| Astellas Pharma US Inc | 1 | $51 |
| Karyopharm Therapeutics Inc. | 2 | $38 |
| Sanofi | 2 | $33 |
| Taiho Oncology, Inc. | 2 | $30 |
| AbbVie | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| AVEO Pharmaceuticals, Inc. | 1 | $16 |
| Array Biopharma Inc | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$1,650
How this compares
$2,981 in reported general payments places this provider in the 70th percentile of 27 hematology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 50 | $1,146,814 |
| RevlimidLenalidomide | 51 | $971,937 |
| KisqaliRibociclib Succinate | 15 | $300,787 |
| BrukinsaZanubrutinib | 17 | $262,152 |
| Abiraterone Acetate | 34 | $112,317 |
| EliquisApixaban | 72 | $61,317 |
| Fentanyl | 23 | $3,064 |
| Anastrozole | 165 | $2,584 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 46 | $1,318 |
| Dexamethasone | 72 | $1,283 |
| Tamoxifen Citrate | 37 | $885 |
| Hydroxyurea | 19 | $512 |
| Ondansetron Hcl | 46 | $481 |
| Amlodipine Besylate | 42 | $424 |
| Potassium Chloride | 46 | $389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $72 | $971,93751 claims |
| NovartisKisqali | $94 | $300,78715 claims |
| Beigene USA, Inc.Brukinsa | $1,650 | $262,15217 claims |
| Lilly USA, LLCOlanzapine | $19 | $7527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 27 hematology providers in Missouri.
Other hematology in Bridgeton
- Morey BlinderSaint Louis$235K
- Stephen OhSaint Louis$143K
- Elaine MajerusSaint Louis$111K
- Richard HammerColumbia$103K
- Govind BhagatSaint Louis$67K
- Amy ZhouSaint Louis$18K
- Shaun HansonSaint Louis$15K
- Stuart KornfeldSaint Louis$4K
- Joshua SinerSaint Louis$1K
- Karim WelayaSpringfield$861
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.